DG Comp official: invisible hand isn’t working in pharma
Pharmaceutical investment incentives are better fueled by longer patent periods than by governments allowing drugmakers to block entry or charge excessive prices, a director at the European Commission’s Directorate-General for Competition has said.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.